(BOPH)

Bohai Pharmaceuticals Group, Inc.

Close Price:
0.45

Change:
0.00

% Change:
0.00 %

Date:
2/1/2012

52 Week:
0.20 - 1.96

Prev Close:
0.45

Open:
0.44

Volume:
10,300

90D Avg. Volume:
11,215

2/1/2012 Range:
0.44 - 0.45

Market Cap:
8,037,000

Trailing PE Ratio:
1.10

Shares Out:
17,860,000

EPS:
0.41

Yield:
0.00

Dividend:
0.00

Dividend Date:
-

Quarter End:
3/31/2012

Bohai Pharmaceuticals Group, Inc.

Website: www.bohaipharma.com

Business Summary: Bohai Pharmaceuticals Group, Inc. and its subsidiaries engage in the production, manufacture, and distribution of herbal pharmaceuticals based on traditional Chinese medicine in the People?s Republic of China. Its medicines are used for various diseases, such as rheumatoid arthritis, viral infections, gynecological diseases, cardio vascular issues, and respiratory diseases. The company?s products include lung nourishing syrup to moisten the lung and relieve coughs; tongbi capsules to promote blood circulation and relieve swelling and pain; tongbi tablets to regulate and fortify the blood promote blood circulation and relieve swelling pain; shangtongning tablets to alleviate pain; zhuangyuan shenhailong medicinal wine to promote kidney function; danqi and fukangning tablets to improve blood circulation; and bazhen yimu cream for menstruation conditioning. Its products also comprise huoxue shujin ting and shujin huoxue tablets to promote blood circulation and relieve blood congestion; anti-flu granules to detoxify the body; compound manshanhong syrup to relieve cough; sanqi shang tablets to promote blood circulation, as well as to relieve blood congestion, numbness, pain, or bruises in the body; stomach nourishing tablets to relieve heartburn, sour stomach, acid indigestion, and stomach upset; and yangxue anshen tablets to improve blood circulation. In addition, the company offers fangfengtongsheng granules to treat fever, headache, constipation, measles, and eczema; zhengxintai capsules to improve kidney function and treat coronary artery disease and angina; tongmai granules to treat ischemic heart and cerebrovascular diseases, arteriosclerosis, and cerebral thrombosis; and bezoar antipyrotic tablets for swelling and pain. Bohai Pharmaceuticals Group sells its products through hospitals, local pharmacies, and retail drug store chains. The company is headquartered in Yantai, China.


No 9 Daxin Road
Zhifu District
Yantai, 264000 China ,
P: 86 53 5685 7928
F: 86 53 5685 7928

BOPH Earnings Calendar

Q1:
Jul
1
 -
Sep
30
Q2:
Oct
1
 -
Dec
30
Q3:
Jan
1
 -
Mar
31
Q4:
Apr
1
 -
Jun
30
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
6/30/2010
 
 
 
$17,725
$0
$11,899
$748
$0
$30,373
$0
$7,895
$0
$17,343
$0
$8,906
$0
$64,517
 
 
$4,427
$4,399
$0
$8,826
$125
$0
$5,482
$0
$0
$14,433
 
$0
$0
$0
$17
$0
$0
$15,318
$2,828
$50,084
$32,742
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
5/31/2009
 
 
 
$2,494
$0
$16,029
$308
$0
$18,831
$0
$8,149
$0
$17,299
$0
$0
$0
$44,279
 
 
$4,485
$5,860
$0
$10,345
$0
$0
$0
$0
$0
$10,345
 
$0
$0
$0
$13
$0
$0
$8,795
$2,693
$33,934
$16,636
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
 
Assets
Current Assets
Cash & Cash Equivalents
Short Term Investments
Net Receivables
Inventory
Other Current Assets
Total Current Assets
Long Term Assets
Property Plant & Equipment
Goodwill
Intangible Assets
Accumulated Amortization
Other Assets
Deferred Long Asset Charges
Total Assets
Liabilities
Current Liabilities
Accounts Payable
Short/Current Long Term Debt
Other Current Liabilities
Total Current Liabilities
Long Term Debt
Other Liabilities
Deferred Long Term Liability Charges
Minority Interest
Negative Goodwill
Total Liabilities
Stockholders' Equity
Misc Stock Options Warrants
Redeemable Preferred Stock
Preferred Stock
Common Stock
Retained Earnings
Treasury Stock
Capital Surplus
Other Stockholder Equity
Total Stockholder Equity
Net Tangible Assets
6/30/2010
 
 
 
$17,725
$0
$11,899
$748
$0
$30,373
$0
$7,895
$0
$17,343
$0
$8,906
$0
$64,517
 
 
$4,427
$4,399
$0
$8,826
$125
$0
$5,482
$0
$0
$14,433
 
$0
$0
$0
$17
$0
$0
$15,318
$2,828
$50,084
$32,742
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
3/31/2010
 
 
 
$15,575
$0
$18,500
$971
$0
$35,046
$0
$7,946
$0
$17,273
$0
$1,899
$0
$62,164
 
 
$4,173
$4,381
$0
$8,554
$121
$0
$5,324
$0
$0
$13,999
 
$0
$0
$0
$16
$0
$0
$9,554
$9,192
$48,165
$30,892
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
11/30/2009
 
 
 
$29
$0
$0
$0
$0
$29
$0
$0
$0
$0
$0
$0
$0
$29
 
 
$4
$0
$0
$4
$400
$0
$0
$0
$0
$404
 
$0
$0
$0
$3
$0
$0
$57
$0
($375)
($375)
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
8/31/2009
 
 
 
$28
$0
$0
$0
$0
$28
$0
$0
$0
$0
$0
$0
$0
$28
 
 
$402
$0
$0
$402
$0
$0
$0
$0
$0
$402
 
$0
$0
$0
$3
$0
$0
$51
$0
($374)
($374)
  
 
 
 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
  
  
  
 
  
  
  
  
  
  
  
  
  
  
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
6/30/2010
$9,488
 
$821
($782)
$4,143
($18)
($438)
$0
$13,215
 
($47)
$0
($7,314)
($7,361)
 
$0
$0
$8,920
($164)
$8,756
$45
$14,655
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
5/31/2009
$7,948
 
$303
$32
($6,054)
($4,483)
$741
$0
($1,513)
 
($804)
$0
$15
($789)
 
$0
$0
$3,963
$0
$3,963
$4
$1,665
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Net Income
Operating Activities
Depreciation
Adjustments To Net Income
Changes In Accounts Receivables
Changes In Liabilities
Changes In Inventories
Changes In Other Operating Activities
Total from Operating Activities
Investing Activities
Capital Expenditures
Investments
Other Investing Activities
Total from Investing Activities
Financing Activities
Dividends Paid
Sale Purchase of Stock
Net Borrowings
Other Financing Activites
Total from Financing Activities
Effect of Exchange Rate Changes
Change in Cash and Cash Equivalents
6/30/2010
$1,736
 
$343
$169
($1,015)
$7,613
$225
$0
$9,070
 
$234
$0
($7,314)
($7,080)
 
$0
$0
($31)
($164)
($195)
($222)
$1,840
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
3/31/2010
$2,673
 
$136
($955)
$4,585
($8,745)
($198)
$0
($2,504)
 
($42)
$0
($9)
($451)
 
$0
$0
$10,019
$0
$10,419
$218
$7,464
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
11/30/2009
($7)
 
$0
$4
$0
($2)
$0
$0
($5)
 
$0
$0
$0
$0
 
$0
$0
$0
$6
$6
$0
$1
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
8/31/2009
($376)
 
$0
$0
$0
$2
$0
$0
($375)
 
$0
$0
$0
$0
 
$0
$0
$400
$0
$400
$0
$25
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
6/30/2010
$59,265
$10,165
$49,100
 
$0
$36,253
$0
$511
$0
$12,847
 
$1,052
$13,388
$926
$12,461
$2,973
$0
$9,488
 
 
$0
$0
$0
$0
$9,488
$0
$9,488
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
5/31/2009
$49,349
$7,975
$41,373
 
$0
$31,347
$0
$0
$0
$10,026
 
$13
$10,039
$184
$9,855
$1,907
$0
$7,948
 
 
$0
$0
$0
$0
$7,948
$0
$7,948
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
Period Ending
Total Revenue
Cost of Revenue
Gross Profit
Operating Expenses
Research Development
Selling General & Administrative
Non Recurring
Others
Total Operating Expenses
Operating Income or Loss
Income from Continuing Operations
Total Other Income/Expenses Net
Earnings Before Interest And Taxes
Interest Expense
Income Before Tax
Income Tax Expense
Minority Interest
Net Income From Continuing Ops
 
Non-recurring Events
Discontinued Operations
Extraordinary Items
Effect Of Accounting Changes
Other Items
Net Income
Preferred Stock And Other Adjustments
Net Income Applicable To Common Shares
12/31/2010
$22,204
$4,681
$17,523
 
$0
$11,105
$0
$244
$0
$6,418
 
$2,966
$9,140
$1,155
$7,985
$1,444
$0
$6,541
 
 
$0
$0
$0
$0
$6,541
$0
$6,541
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
9/30/2010
$17,030
$3,447
$13,582
 
$0
$8,615
$0
$260
$0
$4,968
 
($19)
$4,688
$494
$4,194
$1,182
$0
$3,012
 
 
$0
$0
$0
$0
$3,012
$0
$3,012
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
6/30/2010
$13,922
$2,689
$11,233
 
$0
$8,044
$0
$511
$0
$3,727
 
$225
$2,903
$388
$2,515
$779
$0
$1,736
 
 
$0
$0
$0
$0
$1,736
$0
$1,736
  
  
  
  
 
  
  
  
  
  
  
 
  
  
  
  
  
  
  
 
 
  
  
  
  
  
  
  
3/31/2010
$14,542
$2,596
$11,946
 
$0
$9,139
$0
$0
$0
$2,269
 
$835
$3,642
$388
$3,254
$581
$0
$2,673
 
 
$0
$0
$0
$0
$2,673
$0
$2,673